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Abstract	  
Previously novel histone-derived antimicrobial peptides (HDAPs) were designed based 
on properties of Buforin 2, a peptide whose activity depends on membrane translocation, and 
DesHDAP1 and DesHDAP3 showed significant antibacterial activity.  Their DNA binding, 
permeabilization, and translocation abilities were assessed independently and compared to 
antibacterial activity to determine whether the HDAPs share a mechanism with BF2. DesHDAP1 
translocates effectively across lipid vesicle membranes while DesHDAP3 translocates poorly, 
and none of the DesHDAPs show significant membrane perturbation. Further investigation into 
the role of the proline hinge suggested that a proline hinge can promote membrane translocation 
in some peptides, but that the extent of its effect on permeabilization depends on the peptide’s 
amphipathic properties.  In order to extend the scope of antimicrobial peptide screening in the 
Elmore lab, antimicrobial activity, permeabilization, and translocation screens compatible with 
high-throughput plate-reader software were also developed. While the initial antimicrobial 
activity and permeabilization screens attempted were not appropriate for this system, 
translocation screening was easily adapted to the plate-reader platform. Ultimately information 
about novel HDAPs provides insight into the potential mechanisms of such peptides, while 
development of high-throughput techniques extends the capacity to explore and analyze novel 
peptide libraries.  
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1. INTRODUCTION 
1.1  Modern Antimicrobial Agents and Resistance 
The majority of antibiotics in use today were discovered between the 1930’s and the 
1960’s or are closely related chemical derivatives of these initial antibiotics1. However in the 
more than half century since their discovery many of these antibiotics have been rendered 
obsolete by the emergence of antibiotic-resistant bacteria. M. tuberculosis and S. aureus are both 
common infectious agents that have developed clinically relevant strains resistant to currently 
prescribed antibiotics. Multi-drug resistant tuberculosis accounts for an increasing percentage of 
tuberculosis diagnoses worldwide, with levels approaching 18% in certain eastern European 
countries2. Methicillin resistant S. aureus (MRSA) infections are frequent, accounting for 58% of 
S. aureus hospitalizations, and very serious, causing nearly 19,000 deaths in 20043.Although 
MRSA was once known as a common hospital acquired infection, it has increasingly been 
observed in non-hospitalized populations4. 
Bacteria develop antibacterial resistance either through mutation of existing genes or 
acquisition of resistance genes from other bacteria in the population. Antibiotic resistance may 
be the result of a change to the antibiotic binding site, acquisition of the ability to break down or 
export an antibiotic, or development of pathways that allow a bacteria to tolerate the inactivation 
of the antibiotic target5. For example β-lactamase enzymes hydrolyze the β-lactam ring in 
antibiotics such as ampicillin and cephalosporin6, a single mutation to RNA polymerase renders 
rifampin inactive7, and mutations to the 23S ribosomal subunit greatly decrease the binding 
affinity of macrolide antibiotics like erythromycin8.  
The emergence of antibiotic resistant bacterial strains has not been met with an 
equivalent burst in the discovery of new antibacterial therapeutics. This discrepancy has been 
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attributed to exhaustion of traditional antibiotic sources such as soil bacteria or fungal secretions 
as well as to financial considerations that lead pharmaceutical companies to allocate 
development resources toward medicines that will be taken on an ongoing basis and will 
therefore return greater profit9.  The resulting imbalance between antibiotic resistant organisms 
and effective antibiotics has encouraged a push within the scientific community to promote the 
identification and development of novel antibacterial agents10.  
 
1.2  Antimicrobial Peptides 
Antimicrobial peptides (AMPs) have recently risen to the attention of many researchers 
as a promising new avenue for therapeutic development. These peptides are used in the innate 
immune systems of many organisms, including fish11,12, amphibians13,14, insects15, and 
mammals16. The defining feature of these peptides is a length of between 12-100 amino acids 
and a net positive charge of between +2 and +9. As of January 2012, the antimicrobial peptide 
database has recorded over 1900 antimicrobial peptides from natural sources17.  
While peptides can have antimicrobial activity against viruses, fungi, and even cancerous 
cells, much of the research to date has focused particularly on peptides with antibacterial activity, 
as will this thesis. In order to be effective therapeutic agents, AMPs must be biologically stable 
and capable of preferentially killing bacterial cells without simultaneously exerting harmful 
effects on healthy mammalian cells. Both of these properties are of concern for AMP 
development and are frequent goals of targeted modifications. While susceptibility to biological 
proteases is difficult to eliminate, the sequence of AMPs does play an important, though poorly 
understood, role in prokaryotic cell targeting. Greater understanding of AMP mechanisms is 
critical to eventual efforts toward designing more effective peptides.  
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The cationic nature of antimicrobial peptides seems to be particularly important for AMP 
activity. The net positive charge of AMPs assists in bacterial membrane targeting via 
electrostatic interactions because bacterial membranes have a higher content of negatively 
charged lipid head groups such as phosphatidylglycerol (PG) and a greater negative 
transmembrane potential than do healthy mammalian cells18. An additional factor contributing to 
the observed preference of AMPs for prokaryotic cells is the fact that cholesterol, which is found 
in eukaryotic but not prokaryotic cell membranes, seems to inhibit the activity of antimicrobial 
peptides19.  
While cationic character is important to the function of AMPs, there does appear to be an 
optimal charge. Using the helical peptide L-V13K, Jiang et al investigated the role of net charge 
on the peptide’s antibacterial and hemolytic properties20. The paper investigated the effects of 
changing the net charge of V13K, which normally has a net charge of +7, to net charges ranging 
from -5 to +10. Unsurprisingly, lowering the net charge to +4 or below completely eliminated 
the antibacterial activity of the peptide. As the net charge increased from +7 to +10 the 
antibacterial activity increased; however while the +8 peptide had minimal hemolytic activity, 
both the +9 and +10 peptides were extremely hemolytic. This suggests that there may be an 
optimum charge for the creation of useful therapeutics capable of targeting bacterial membranes 
without exerting harmful effects on host cells.  
Antimicrobial peptides can adopt many conformations including alpha helices, beta 
sheets, polyproline extended helices, random coils, and loops stabilized by disulfide bridges. 
Alpha helical peptides are both common and extremely well studied, particularly in relationship 
to the optimal distribution of residues about helical faces. While Park et al observed a direct 
correlation between alpha helicity and antimicrobial activity from their study of truncations of 
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Buforin 221, this does not appear to be a universal trend. For example increasing the hydrophobic 
content of the helical peptide V13K led the peptides to adopt more helical conformations, but 
also produced higher self-aggregation and hemolytic behaviors22. Other histone-derived 
antimicrobial peptides have also failed to exhibit this correlation between peptide helicity and 
general antimicrobial activity23.  
Although the net charge and conformation of AMPs play important roles in their activity, 
the most important parameter may be the distribution of the charges and hydrophobic residues 
about the helix. Studies suggest that an amphipathic charge distribution with defined cationic and 
hydrophobic faces is optimal for AMP activity22. Peptides with segregated areas of charged 
residues and hydrophobic residues can target and interact with the cell membrane 
electrostatically through their cationic side chains and insert into or cross the lipid bilayer 
because of favorable interactions between hydrophobic regions of the peptide and lipid tails. 
However, excessive hydrophobic character can lead to peptide aggregation and hemolysis.  
Antimicrobial peptides have several potential advantages as therapeutic agents. Many 
AMPs are active against a broad range of medically relevant bacteria, and some also demonstrate 
selective ability to target and kill fungal or cancerous cells24. Antimicrobial peptides target 
nonspecific cell components such as the cell membrane, making it difficult for bacteria to 
develop resistance through minor mutations.   
The fact that AMPs have existed as a part of innate immune systems for so many years 
demonstrates that they are robust antimicrobial agents. However, this has also given ample time 
for certain microorganisms to develop mechanisms to resist AMP lethal effects. Some bacteria 
manage to reduce their overall membrane surface charge, preventing the initial electrostatic 
attraction, while others encode enzymes for proteolytic degradation of AMPs25.   However, the 
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continued efficacy of AMPs against wide ranges of infectious organisms suggests that AMP 
resistance may be less common and easily evolved than resistance to traditional antibiotics. 
 
1.3  AMP Mechanisms 
Antimicrobial peptides are characterized by 3 general mechanisms of bactericidal action 
resulting from interaction between the peptide and the bacterial membrane. The first two 
mechanisms both involve loss of membrane barrier function as the primary cause of cell death 
(figure 1). First, peptides may cause nonspecific membrane disruption in a detergent-like 
fashion, as in the “carpet model”26. Secondly peptides may associate with each other to form 
well-defined pores across the membrane through which fluids and important solutes can pass, 
described by “toriodal pore”27 and “barrel-stave”28 models. While both of these models propose a 
stable pore of aggregated peptide, they differ in the conformation of the membrane lipids around 
the pore and the membrane-lipid interactions. In the barrel-stave model there is no membrane 
deformation, so the peptide pore contacts the phospholipid heads near either edge of the 
membrane and the hydrophobic tails in the middle of the membrane (figure 1B). In contrast, the 
torroidal pore model suggests that lipids deform inwards around the pore such that only the head 
groups are in contact with the peptide at any point on the pore (figure 1C). 
Magainin II is a 23 amino acid helical AMP initially isolated from Xenopus laevis14, 
which has been particularly well characterized through ongoing efforts to understand the 
mechanisms of lytic peptides. NMR and fluorescence quenching experiments have shown that 
magainin initially associates with bacteria in an orientation parallel to the plane of the membrane 
before aggregating and inserting into the membrane once a critical peptide/lipid ratio is 
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reached19. The resulting membrane pores allow K+ efflux and loss of barrier function, ultimately 
leading to cell death.  
Many biological signaling molecules interact with and cross cell membranes through 
binding to specific receptors. In order to assess whether AMP interactions with bacterial 
membranes depend on recognition of specific receptors or lipid binding sites, researchers turned 
to the chiral properties of amino acids and protein secondary structures. Amino acids, lipid head 
groups, and protein secondary structures are chiral and as a result interact specifically with other 
chiral molecules. This is an important issue in drug design, as often only one enantiomer is 
capable of effectively binding to the required biological target. If AMP interactions with 
bacterial cells were mediated through specific receptors or particular interactions with lipid 
heads, D- and L- enantiomers would show different antibacterial activities. However when 
AMPs composed entirely from D-amino acids were compared to their L-amino acid 
counterparts, the same antibacterial activity and selectivity were observed29. Thus AMPs target 
and interact with cellular membranes through a mechanism that does not depend on specific 
recognition of chiral proteins or lipids. This assertion is further supported by the ability of 
peptides to interact with lipid vesicles, which have only the phospholipids without any of the 
receptors or proteins found in living cell membranes. 
 The third mechanism by which AMPs may exert their antimicrobial activity differs from 
the previous two in that it does not rely on a loss of barrier function to kill the bacterial cell. 
Instead, these AMPs cross the cell membrane without grossly disrupting the membrane integrity. 
Once the peptides reach the cell interior, they can execute their bactericidal function through 
interfering with any number of essential cellular processes. Although they are less common, 
AMPs that exert their activity by crossing the cell membrane and interacting with intracellular 
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components have many therapeutically promising features. The intracellular activity means that 
these peptides address a wide range of targets. AMPs that use this mechanism include 
indolicidin, a neutrophil-derived AMP that inhibits bacterial DNA synthesis30 and proline-rich 
peptides whose intracellular target(s) have not been identified31. 
 
1.4  Histone Derived Antimicrobial Peptides 
BF2, the most thoroughly studied membrane-translocating AMP, is derived from a 
defensive peptide identified in the stomach of the giant toad Bufo bufo garagrizans and shows 
broad spectrum activity against gram positive and gram negative bacteria13.  BF2 is capable of 
entering bacterial cells without significantly disrupting their membranes21 through a process 
dependent on the presence of a helix-breaking proline residue32. The proline residue disrupts the 
Figure	  1:	  Commonly	  accepted	  antibacterial	  mechanisms	  of	  AMPs.	  Upon	  approaching	  the	  
membrane,	  the	  peptides	  may	  align	  parallel	  to	  the	  membrane	  (A),	  insert	  into	  the	  
membrane	  perpendicular	  to	  the	  membrane	  plane	  (B-­‐C),	  or	  cross	  the	  membrane	  and	  
enter	  the	  cell	  (D).	  Note	  that	  in	  the	  barrel-­‐stave	  mechanism	  (B)	  the	  lipid	  heads	  and	  
hydrophobic	  tails	  come	  in	  contact	  with	  the	  peptide	  pore,	  whereas	  in	  the	  toroidal	  pore	  
mechanism	  (C)	  the	  lipid	  membrane	  curves	  inward	  such	  that	  only	  the	  lipid	  heads	  contact	  
the	  peptide.	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helical structure of BF2, allowing it more flexibility to adopt ideal amphipathic conformation in 
contact with cell membranes. Proline seems to be ideally situated in its position as the 11th 
residue in the peptide, as moving it one turn towards either the N- or C- terminus of the peptide 
results in a dramatic decrease in antibacterial strength33.  
Interestingly, BF2 shares complete sequence homology to a DNA binding portion of 
histone H2A and has a high affinity for DNA. BF2’s antimicrobial activity is dependent on its 
DNA-binding ability, as evidenced by a dramatic decrease in antimicrobial activity when 
important DNA binding residues are altered34.  Although BF2 itself does not show appreciable 
anti-cancer activity, a synthetic analog consisting of buforin II with a deletion of the N-terminal 
random coil and an extension of the C-terminal [RLLR] repeat showed both antibacterial activity 
comparable to that of BF232 as well as potent activity against more than 60 types of cancerous 
cells35.  
The potency of BF2 suggested that histones might be a promising and largely unexplored 
source of template material for the design of antimicrobial peptides. Whole histones display 
some antimicrobial properties, are capable of entering cells without causing membrane 
disruption, and have even been used as transfection agents to deliver DNA cargoes to 
intracellular targets36. Both whole histones and peptides homologous to histone fragments have 
been identified as components of innate immunities37. Several antimicrobial peptides with 
sequence homology to histone subunits have been isolated from natural sources, including 
parasin from catfish11, hipposin from Atlantic halibut12, and onchorhyncin II from rainbow 
trout38.  
Based on the properties of BF2 that are required for antibacterial activity, Tsao et al 
designed three novel histone-derived antimicrobial peptides homologous to DNA-binding 
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portions of histone subunits23. Each peptide was chosen for its predominantly helical structure 
broken by a proline hinge as well as the presence of multiple positive charges. When tested, the 
three novel peptides all displayed activity against a range of gram-positive and -negative 
bacteria. Interestingly, the peptides demonstrate different patterns of efficacy against particular 
bacterial strains. Furthermore differential changes to turbidity upon peptide addition suggest that 
the three peptides may not share an antimicrobial mechanism EXPAND. While this small-scale 
design success suggests the utility of histones as design templates for rational creation of novel 
AMPs, there has not yet been any systematic analysis of histones as source material for 
antimicrobial peptides. 
 
1.5 Cell Penetrating Peptides 
A closely related and sometimes overlapping class of peptides with therapeutic potential 
are cell penetrating peptides (CPPs) (figure 2). Like AMPs, these small peptides interact with 
cell membranes through electrostatic interactions, but many CPPs cross the lipid bilayer and 
enter into the cell interior without causing any membrane disruption or adversely affecting the 
cell. CPPs are of interest as 
delivery vectors because they 
can be covalently or 
electrostatically bound to 
cargo, which they then 
transport with them to the 
interior of the cell. This process 
has been successfully used to 
Figure	  2:	  Although	  they	  are	  sometimes	  addressed	  as	  
completely	  separate	  areas	  of	  research,	  AMPs	  and	  CPPs	  
overlap	  in	  the	  form	  of	  cell-­‐penetrating	  AMPs	  such	  as	  BF2.	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promote the uptake of molecules such as small molecule pharmaceuticals39, siRNA40,41, 
proteins41, or liposomes42.   
Like AMPs, CPPs are short and usually contain cationic and hydrophobic residues 
arranged in an amphipathic conformation43. Although the role of endocytosis in CPP uptake is a 
topic of ongoing investigation, it appears that the electrostatic interaction between charged 
residues and cell membranes is important to CPP targeting and activity44. In the case of 
eukaryotic cells, it is hypothesized that negatively charged heparin sulfate is the important 
attractor, supported by the observation that cells lacking heparin sulfate show reduced 
internalization of CPPs45.  
In contrast to this general trend, one anionic CPP has been described. SAP (E) was 
created by replacing each arginine in the SAP peptide with glutamine, forming a peptide with an 
extended polyproline helix and a net charge of -3 46.  This peptide was efficiently internalized 
into 4 cancerous cell lines through a mechanism that showed minimal dependence on the 
presence of heparin sulfate, suggesting that at least some CPPs may not use electrostatic 
attractions to mediate initial cellular approach. As with AMPs, investigators still have no method 
for design or prediction of CPPs based on conserved features or sequences.  
 
1.6 Peptide Discovery and Modification 
Naturally occurring antimicrobial peptides, identified though analysis of mucous 
membrane secretions or organ tissue samples from various organisms, account for the majority 
of AMPs in the literature. However, after the initial discovery, many studies look at particular 
fragments of or substitutions to these peptides in order to learn about the peptides’ mechanisms. 
Alterations that reduce or eliminate antimicrobial activity provide information about portions of 
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the peptide that are important to antibacterial activity and are often used in the determination of 
the peptide’s mechanism of action. 
Many research groups have sought specific mutations that could improve desired 
characteristics of AMPs. Ideal therapeutic treatments must not only have broad spectrum activity 
against pathogens, but must also be soluble, resistant to degradation in vivo, and minimally 
harmful to healthy cells. Of particular concern to the AMP community are the issues of 
enzymatic degradation of AMPs by proteases and detrimental effects of AMPs on mammalian 
cells (usually measured by hemolysis of red blood cells).  
One particularly promising trend that appears to jointly address the issues of hemolytic 
activity and susceptibility to enzymatic degradation is the incorporation of D-amino acids into 
AMPs. Naturally produced proteins are composed exclusively of L- amino acids, but the D-
enantiomers can be chemically synthesized. AMPs synthesized with one or more D-amino acids 
have demonstrated equivalent antimicrobial activity compared to their L-enantiomers while 
resisting proteolytic degradation47–49. Single D-amino acid substitutions can also affect the 
folding of a peptide50, while peptides composed entirely of D-amino acids retain the same 
secondary structure with opposite chirality as compared to their L-enantiomers47. In particular 
the increased resistance to proteolytic degradation suggests that incorporation of D-amino acids 
might be a promising avenue for AMP therapeutic development. 
Other unnatural amino acid substitutions have also been investigated in hopes of 
improving in vivo peptide stability. Fluorinated analogs of buforin and magainin retained 
antimicrobial activity comparable to the unmodified peptides and exhibited greater resistance to 
degradation by trypsin51. In the case of the buforin analogs, fluorinated peptides also displayed 
greatly reduced hemolytic activity.  While such studies are able to make important and relevant 
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improvements to the activities of current AMPs, they are limited by issues such unnatural amino 
acid availability and peptide synthesis, which limit the number of modified peptides that can 
reasonably be tested in a single experimental design. 
 
1.7 High Throughput Screening for Antimicrobial Discovery 
Antimicrobial peptides used for research are usually chemically synthesized, and one of 
the limiting factors in AMP research is the high cost of peptide production. However, despite the 
short length of AMPs, the number of naturally occurring amino acids means that the field of 
potential peptides is extremely large. Many studies have focused on truncating, fusing, or making 
specific substitutions to peptides discovered from natural sources. However, despite the number 
of AMPs described to date, our ability to predict or design novel AMPs remains poor.  
Although scientists lack a global understanding of the features that make an effective 
antimicrobial peptide, some peptides designed from repeating elements that occur frequently in 
AMPs have demonstrated antimicrobial activity.  Xie et al identified two commonly recurring 
motifs among membrane-binding peptides from a random peptide library and demonstrated that 
peptides composed of 6 repetitions of the motifs showed both antimicrobial activity and 
prokaryotic membrane selectivity52. While investigating the properties of BF2, Park et al 
identified the C-terminal helical region as a motif characteristic of its antimicrobial activity and 
noted that a peptide composed of 5 repetitions of this 4 amino-acid motif showed strong 
antibacterial activity against a range of bacterial strains21.  
In order to efficiently identify novel AMPs and add to the data regarding the properties 
that create an effective antimicrobial peptide, many research groups have turned to high 
throughput screening (HTS). HTS techniques use 96 or 384 well plates to screen small volumes 
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of potentially active compounds using assays that can detect desirable traits with plate reader 
software. Kim and Cha used a fusion of enhanced cyan and yellow fluorescence proteins to 
identify proteins with membrane permeabilization activity by monitoring a decrease in 
fluorescence resonance energy transfer (FRET) fluorescence53. Under neutral pH conditions, 
such as those within an intact cell this protein was capable of transferring energy from the cyan 
protein to the yellow protein because both were stable and correctly folded. However, in lower 
pH conditions the yellow fluorescent protein became unstable and was no longer able to accept 
energy transfer from the cyan protein. Thus when bacterial cells were suspended in a solution 
with a lower external pH, membrane permeabilization was identifiable by the decrease in FRET 
as the fusion protein from lysed cells unfolded in the low pH environment. This technique was 
capable not only of identifying peptides with membrane-lytic properties but also of 
characterizing dose-response curves and quantitative analysis.  
Advances in analytical instruments and computational power have enabled exciting new 
screening techniques for the analysis of enormous datasets of visual material. One emerging 
technique, called high-content screening, images fluorescently labeled cells from each well of 96 
or 384 well plates then uses complex image analysis software to detect morphological changes 
based on defined parameters such as changes in shape or internalization and localization of 
labeled molecules54. While this analysis technique requires specialized microscopy equipment, 
image analysis programs, and data storage, it has the promising ability to collect data in 
representative infectious scenarios such as the invasion of eukaryotic cells by bacteria. 
Additionally, separate stains for eukaryotic nuclei and invasive bacteria allow the simultaneous 
evaluation of cytotoxicity and antibacterial activity in an in vivo system.  
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Other studies have approached AMP discovery using the simplified system of isolated 
lipid vesicles to identify peptides that lyse or cross lipid bilayers. Wimley et al used vesicle 
leakage to identify 10 soluble membrane active peptides from a library of 16,384 peptides55. 
These peptides also showed broad-spectrum antimicrobial activity despite significant variation in 
length, net charge, and helical content56. In a subsequent study, the group used an orthogonal 
screen to simultaneously monitor membrane permeabilization through the chelation of terbium 
(III) and dipicolinic acid (DPA) and peptide translocation through chymotrypsin cleavage of an 
AMC fluorophor57. This assay identified 18 peptides capable of crossing lipid bilayers without 
causing significant membrane leakage. These peptides did not bear any resemblance to 
previously described AMPs and were characterized by overrepresentation of hydrophobic 
residues and a low net positive charge. The identified peptides were confirmed as being able to 
enter Chinese hamster ovary cells in in vivo experiments. This type of screening illustrates that 
screening peptides in a simplified vesicle system is a viable route to the identification of novel 
AMPs with particular properties  
Ultimately high throughput screening will be important for both the discovery of novel 
antimicrobial peptides from random or semi-random peptide libraries as well as for systematic 
analysis of the properties that confer antimicrobial activity in a small peptide. Analysis of large 
libraries may also be able to shed light on the properties that determine the mechanism of 
peptides and ultimately lead to the ability to rationally design peptides with desired therapeutic 
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1.8 Goals of This Thesis 
This thesis will address the issue of antimicrobial peptide design and mechanism study 
from two perspectives. Firstly it will explore the utility of histones as source material for 
antimicrobial peptide design through the characterization and analysis of three previously 
described novel histone derived antimicrobial peptides23. This type of study can illuminate AMP 
properties that contribute to antibacterial activity and determine a peptide’s mechanism of action. 
In an effort to enable the further exploration of histone fragments with antimicrobial activity, this 
paper will also report efforts toward the establishment high-throughput techniques capable of 
identifying peptides with antimicrobial activity and providing preliminary mechanistic 
information. Such screens would enable rapid screening of large libraries of histone fragments 
and easy identification of peptides warranting further detailed research. Ultimately both the 
knowledge of peptide mechanisms provided by detailed study and the identification efforts made 
possible through high-throughput screening will be necessary for the continued understanding 
and development of antimicrobial peptides as novel therapeutic agents to combat emerging and 
evolving infectious agents.  
  
	   16	  
2. MATERIALS AND METHODS 
2.1 Peptides 
Buforin II F10W, Magainin 2, DesHDAP1, DesHDAP2, and DesHDAP3 were 
synthesized and purified by GenScript (Piscataway, NJ) to > 95% purity. Proline to alanine 
mutant versions of each designed peptide as well as peptides with an N-terminal biotin group 
were also obtained at > 95% purity. All peptides had an unmodified C-terminus with a free 
carboxylic acid, and peptides that did not have an N-terminal biotin group had a free amine 
group at the N-terminus with no other modification. Peptides were dissolved in nanopure H2O 
and stored at − 20 °C. Peptide concentrations were determined from the absorbance signals of 
native tryptophan residues at 280 nm. Absorbance was measured with a Biorad SmartSpec Plus 
spectrophotometer (Philadelphia, PA) or a Thermo Scientific Nanodrop 2000 (Wilmington, DE).  
 
2.2 Relationship between Colony-Forming units and Optical Density  
A bacterial colony was picked from frozen stock and grown in Luria broth (LB) (20% LB 
w/v, Sigma, St. Louis, MO) overnight. The overnight culture was diluted 1:500 into new LB 
medium and allowed to grow to an optical density of between 0.2 and 0.5. The solution was 
serially diluted in LB media, and 100 µL aliquots of the 1:104, 1:105, and 1:106 dilutions were 
Species Name Catalog Number OD600 conversion factor 
Escherichia coli ATCC #29212 2.5 x 108 
Staphylococcus aureus Carolina #155554A 3.66 x 108 
Serratia marcesans Carolina #155450A 2.58 x 108 
Bacillus subtilis ATCC #6051 8.76 x 107 
Enterococcus faecalis ATCC #29212 1.11 x 108 
Table	  1:	  Conversion	  factors	  used	  for	  calculations	  of	  bacterial	  concentration	  in	  solution.	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plated on LB agar (20 % LB w/v, 10% bacto agar w/v, Sigma, St Louis, MO). The plates were 
incubated overnight at 37oC, then colonies were counted and used to determine the relationship 
between optical density and colony-forming units per mL. CFU conversion factors found in this 
manner were used for all subsequent evaluations of bacterial concentrations. 
 
 
2.3 Radial Diffusion Assay for Peptide Activity 
A bacterial colony was picked from frozen stock and grown in tryptic soy broth (TSB) 
(30% TSB w/v) overnight. The overnight culture was diluted 1:500 into new TSB medium and 
allowed to grow for an additional 2.5 hours. The bacterial suspension was pelleted by 
centrifugation at approximately 880 x g, resuspended in sterile phosphate buffer (10 mM sodium 
phosphate, pH 7.4), and pelleted again. The resulting pellet was resuspended in phosphate buffer, 
and the concentration in colony-forming units per milliliter was determined as using the 
conversion factors found above (table 1). Underlay agar (9.1 mM phosphate, 10 g/L agarose, 
0.27 g/L TSB medium, pH 7.4) was melted in the microwave then allowed to cool to 42oC. 4 x 
106 CFU of bacteria in solution were added to 10mL of molten agar, vortexed, poured into a 15 x 
1000 mm petri dish, and allowed to solidify at room temperature.  A Pasteur pipette attached to a 
vacuum line via a bleach trap was used to create wells in the agar. The wells were filled with 2.5 
µL of 3 x 10-4 M peptide solution. The plates were then incubated at 37oC for 3 hours, at which 
point 10 mL of molten overlay agar (60 g/L TSB, 10 g/L agarose) was added onto the underlay 
and allowed to cool. The plates were then incubated overnight at 37oC and the diameter of 
bacterial clearance was measured under 7x magnification.  
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2.4 Absorbance Versus Time Profile  
An E. coli colony was picked from frozen stock and grown in tryptic soy broth (TSB) (30 
g/L TSB medium) overnight. The overnight culture was diluted 1:500 into new TSB medium and 
allowed to grow for an additional 2.5 hours. The bacterial suspension was pelleted by 
centrifugation at approximately 880 x g, resuspended in sterile phosphate buffer (10 mM sodium 
phosphate, pH 7.4), and pelleted again. The resulting pellet was resuspended in phosphate buffer, 
and the concentration in colony-forming units per milliliter was determined and adjusted to 5 x 
106 CFU/mL in phosphate buffer. 150 µL of the bacterial solution was placed in the wells of a 96 
well plate. Peptide was added to a final concentration of 10-4 M and the absorbance at 600 nm 
was monitored at 15 s intervals on a SpectraMax plate-reader (Molecular Devices, Sunnydale, 
CA). In order to assess cell viability during this procedure, 10 µL samples were removed from 
each well at appropriate time points, diluted 1:100 in TSB, and allowed to grow overnight on LB 
agar (20% LB w/v, 10% bacto agar w/v) at 37oC. 
 
 
2.5 Propidium Iodide Uptake Assay 
E. coli picked from a frozen stock were allowed to grow overnight in TSB media (30g/L 
TSB medium).  The overnight culture was diluted 1:500 into new TSB medium and allowed to 
grow for an additional 2.5 hours. The bacterial suspension was pelleted by centrifugation at 
approximately 880 x g, resuspended in sterile phosphate buffer (10 mM sodium phosphate, pH 
7.4), pelleted again, and resuspended in sterile phosphate buffer to a final optical density of 0.5. 
Propidium iodide (PI) was added to a final concentration of 20 µg/mL and the system allowed to 
equilibrate. PI was excited at 535nm and fluorescence measured at 617nm on a Varian Cary 
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Eclipse fluorescence spectrophotometer (Agilent Technologies, Santa Clara, CA). After the cells 
had equilibrated, peptide was added to a final concentration of 2µM and PI fluorescence was 
monitored for the following 40 minutes. Increase in fluorescence due to peptide was determined 
by comparing the fluorescence 5 minutes after peptide addition to the averaged value for the 
fluorescence in the minute prior to peptide addition. Reported numbers represent the averages of 
at least 4 independent experiments.  
 
2.6 Thiazole Orange Displacement Assay 
A Varian Cary Eclipse fluorescence spectrophotometer (Agilent Technologies, Santa 
Clara, CA) was blanked with STE buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 8.0). A 
1 mL mixture of dsDNA (1.10 µM base pair concentration) and thiazole orange (0.55 µM) was 
made in STE buffer. The dsDNA (IDT, Coralville, IA) used was derived from DNA adjacent to 
the histone H2A region identical to the BF2 sequence in a histone·DNA crystal structure 
(AAATACACTTTTGGT). Maximum fluorescence intensity was measured 5 min after DNA 
addition (excitation wavelength: 509 nm; emission wavelength: 527 nm). The solution was then 
titrated with successive additions of 78 µM peptide solution. The decrease in fluorescence was 
measured 5 min after each addition of peptide until the fluorescence intensity decreased to ~50% 
of the maximum fluorescence. The peptide concentration at which fluorescent intensity was 
decreased to half (C50) was extrapolated using the linear fit function on Microsoft Excel. 
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2.7 LIVE/DEAD® Assay 
The LIVE/DEAD® assay was performed according to manufacturer instructions 
provided by Invitrogen (Grand Island, NY). Briefly, E. coli were grown overnight in LB medium 
(20% LB w/v), diluted 1:1000 in LB, allowed to grow to mid-log phase, and pelleted by 
centrifugation at ~880 x g. Pelleted bacteria were resuspended in a small volume of sterile 
phosphate buffer (10 mM sodium phosphate, pH 7.4). The resuspended bacteria solution was 
split in half and incubated in either phosphate buffer or 70% ethanol for 1 hour at room 
temperature. After incubation, the bacteria were once again pelleted by centrifugation and 
resuspended in phosphate buffer. Optical density of each solution was measured and used to 
calculate bacterial concentration in colony forming units/mL, then solutions were adjusted to 1 x 
108 CFU/mL. A standard curve was constructed by combining live and ethanol-killed bacteria in 
known ratios to a total volume of 100 µL in the wells of a 96 well plate or a total volume of 3 
mL in a quartz cuvette. SYTO9 and propidium iodide dyes were combined and diluted to prepare 
a concentrated stain solution (2X for plate reader, 10x for fluorimeter), which was added to the 
bacterial solution for a final concentration of 5.01 µM SYTO9 and 30 µM propidium iodide. 
After dye addition, the solutions were incubated for 15 minutes at room temperature while 
protected from light. At this time the fluorescence spectra were measured using a SpectraMax 
M3 multi-mode microplate reader (Molecular Devices, Sunnyvale, CA) or Varian Cary Eclipse 
fluorescence spectrophotometer (Agilent Technologies, Santa Clara, CA). Both dyes were 
excited at 485 nm; SYTO9 fluorescence was measured at 530 nm and propidium iodide 
fluorescence was measured at 630 nm. The standard curve, created using a linear regression on 
Microsoft Excel, was used to establish a relationship between ratio of SYTO9/PI fluorescence 
and the % live cells. 
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In order to determine the viability of bacteria exposed to antibacterial agents, bacteria 
were grown, pelleted, incubated in phosphate buffer, quantified, and diluted to 1 x 108 CFU/mL 
as described above. 100 µL of the bacterial solutions were aliquoted into the wells of a 96 well 
plate, and appropriate peptide or antibiotic was added to a final concentration of 1 x 10-5 M. 
Bacteria were incubated with the peptide for 30 minutes at 37oC. SYTO9 and propidium iodide 
dyes were combined and diluted to prepare a 2X stain solution (10.02 µM SYTO9, 60 µM PI). 
100 µL of the stain solution was added the bacterial solution in the plates and incubated for 15 
minutes at room temperature protected from light. At this time the fluorescence spectra were 
measured using a SpectraMax M3 multi-mode microplate reader (Molecular Devices, Sunnyvale, 
CA). Both dyes were excited at 485 nm; SYTO9 fluorescence was measured at 530 nm and 
propidium iodide fluorescence was measured at 630 nm.  
 
2.9 Turbidity-based Antimicrobial Activity Assay 
An E. coli colony was picked from frozen stock and grown in tryptic soy broth (TSB) (30 
g/L TSB medium) overnight. The overnight culture was diluted 1:500 into new TSB medium and 
allowed to grow for an additional 2.5 hours. The bacterial suspension was pelleted by 
centrifugation at approximately 880 x g, resuspended in sterile phosphate buffer (10 mM sodium 
phosphate, pH 7.4), and pelleted again. The pellet was resuspended in sterile phosphate buffer, 
and the optical density at 600nm was used to determine the concentration of the solution. 
Bacteria were diluted to 1 x 103 CFU/mL in liquid testing medium (0.3 g/L TSB, 0.1M 
NaH2PO4, 0.15M NaCl, pH 7.25). 100 µL of this solution was placed in the wells of a 96 well 
plate, and treated with the appropriate concentration of peptide (final peptide concentrations 
tested ranged from 5 to 30 µM). Plates were covered tightly with plastic wrap to prevent 
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evaporation and incubated at 37oC for 3 hours. After this incubation, 100 µL of 2X TSB (60 g/L) 
was added to each well and the plates were re-covered and incubated at 37oC overnight. Wells 
were scored visually using a binary “growth”/”no growth” system after 14-17 hours of overnight 
growth. 
 
2.10 Confocal Microscopy with LIVE/DEAD Dyes 
Bacteria were grown, pelleted, and incubated in either phosphate buffer or 70% ethanol 
as described in the Live/Dead procedure. Bacterial solutions were incubated with staining 
solution (5.01 µM SYTO9, 30 µM propidium iodide) for 15 min at room temperature protected 
from light, then placed on a poly-L-lysine coated slide and observed under 1000X magnification 
using a Leica TCS-SP1 confocal microscope with excitation at 488 nm.  
 
2.11 Lipid Vesicle Preparation and Quantification 
Phospholipids dissolved in chloroform were purchased from Avanti Polar Lipids 
(Alabaster, AL). N2 stream was used to evaporate the chloroform off of a mixture of 
phosphatidylcholine (PC): phosphatidylglycerol (PG) and the resulting lipid cakes were kept in a 
desiccator overnight. Anhydrous lipid cakes were rehydrated in appropriate solution and 
subjected to five freeze–thaw cycles. Vesicles were extruded 21 times through a nuclepore track 
etch membrane with 0.1 µm pores (Whatman, United Kingdom) in an Avanti Polar Lipids 
extruder at a temperature of ~40oC to ensure uniform vesicle size.  
Vesicle concentration was measured in triplicate as a function of total phosphorus content 
in solution as described by Avanti (http://www.avantilipids.com/index.php?option=com_ 
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content&view=article&id=1686&Itemid=405). Briefly, a standard curve was constructed by 
treating various volumes of 0.65 mM phosphorus (KH2PO4) solution with 450 µL of 8.9 N 
sulfuric acid prior to 25 minutes of baking at 180oC. At this point 150 µL of H2O2 was added and 
the solutions were baked at 180oC for an additional 30 min. The solutions were removed from 
the oven, and water, ammonium molybdate, and ascorbic acid were added. Solutions were boiled 
in a water bath, for 7 minutes, and absorbance was determined at 820 nm. The standard curve 
was determined using a linear fit on Microsoft Excel. The total phosphorous content of the 
extruded vesicle solution was determined by subjecting a small volume of vesicle solution to the 
same procedure described above for the standards. The standard curve was used to determine the 
total phosphorous content in the vesicle sample based on the absorbance.  
 
2.12 Calcein Self-Quenching Assay for Permeabilization 
Phospholipids dissolved in chloroform were purchased from Avanti Polar Lipids 
(Alabaster, AL). N2 stream was used to evaporate the chloroform off of a 3:1 mixture of 
phosphatidylcholine (PC): phosphatidylglycerol (PG) and the resulting lipid cakes were kept in a 
desiccator overnight. Anhydrous lipid cakes were rehydrated in 50 mM calcein (Sigma, St. 
Louis, MO) in TES buffer (100 mM NaCl, 10 mM TES, 0.1 mM EDTA, pH 7.4), and vesicles 
were prepared and quantified as described above. Peptides were added to added to wells of a 96 
well plate such that their final concentration in solution would be 6µM.  Equivalent volumes of 
water and 10% Triton-X100 were used as negative and positive controls, respectively. Vesicles 
were diluted to a concentration of 3 x 10-5 M and 200 µL of the vesicle solution was added to the 
wells containing peptide. Fluorescence was monitored using a SpectraMax M3 multi-mode 
microplate reader (Molecular Devices, Sunnyvale, CA) (ex: 470 nm, em: 509 nm). Percent 
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permeabilization was determined according to the following formula, using water and triton-X 
treated wells as 0% and 100% respectively:  
 
 
2.13 Trypsin Digestion Translocation Assay 
Phospholipids dissolved in chloroform were purchased from Avanti Polar Lipids 
(Alabaster, AL). N2 stream was used to evaporate the chloroform off of a 50:45:5 mixture of 
phosphatidylcholine (PC): phosphatidylglycerol (PG): 5-dimethylaminonaphthalene-1-sulfonyl 
phosphatidylethanolamine (DNS-PE) and the resulting lipid cakes were kept in a desiccator 
overnight. Vesicles were rehydrated in a solution of 0.2 M porcine trypsin (Sigma Aldrich T-
0303) in HEPES buffer (10 mM HEPES, 45 mM NaCl, 1 mM EDTA, pH 7.4) for the 
experimental condition or a solution of 0.2 M porcine trypsin and 2 M trypsin-chymotrypsin 
inhibitor (Sigma Aldrich T-9777) in HEPES buffer for the control condition. Vesicles were then 
prepared and quantified based on total phosphorous content as described above. Phosphorous 
content of control vesicles was blanked against a solution containing the equivalent volume of 
trypsin-chymotrypsin inhibitor but lacking any vesicles. Vesicles were diluted to a final 
concentration of 0.25 mM in a solution containing 10X molar equivalent of trypsin inhibitor as 
compared to the trypsin in the vesicle solution. Peptides were prepared at a concentration of 2.5 x 
10-4 M in nanopure water and 2 µL of peptide solution was placed in each well of opaque 96 well 
plates (VWR, Radnor, PA). 200 µL of the vesicle-containing solution was added to each well 
and fluorescence monitoring begun immediately. Fluorescence was measured using a 
SpectraMax M3 multi-mode microplate reader (Molecular Devices, Sunnyvale, CA) using an 
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excitation of 280 nm and measuring emission at 525 nm. Fluorescence was monitored for 25 
minutes, and percent decrease determined by dividing the average fluorescence in the final 
minute by the fluorescence at t = 0.  Translocation ratio of the experimental sample relative to 
the control condition was determined using the following formula: 
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3. NOVEL HISTONE DERIVED ANTIMICROBIAL PEPTIDES 
Previous work resulted in the successful design of three histone-derived antimicrobial 
peptides (HDAPs) based on the important properties of BF223. Like BF2, each of the novel 
HDAPs was polycationic, amphipathic, and primarily helical with a single helix-breaking proline 
hinge (table 2). Each of the three novel HDAPs displayed antimicrobial activity against a variety 
of gram positive and gram-negative strains. Because the proline residue is known to play an 
important role in BF2’s antimicrobial activity, proline-to-alanine mutants of each peptide were 
also synthesized and assessed.  
 
Peptide Histone Subunit 
Source 
Amino Acid Sequence # of Amino 
Acids 
Buforin II (BF2) H2A TRSSRAGLQWPVGRVHRLLRK 21 
BF2 P11A H2A TRSSRAGLQWAVGRVHRLLRK 21 
Magainin 2 - GIGKFLHSAKKFGKAFVGEIMNS 23 
DesHDAP1 H2A ARDNKKTRIWPRHLQLAVRN 20 
DesHDAP1 
P11A mutant 
H2A ARDNKKTRIWARHLQLAVRN 20 
DesHDPA2 H3 HRYRPGTVALREIRRYQKST 20 
DesHDAP2 
P5A mutant 
H3 HRYRAGTVALREIRRYQKST 20 
DesHDAP3 H4 KVLRDNIQGWTKPAIRRLARRG 22 
DesHDAP3 
P13A mutant 
H4 KVLRDNIQGWTKAAIRRLARRG 22 
 
 
Table	  2:	  Sequences	  of	  buforin	  II,	  DesHDAP1,	  DesHDAP3,	  and	  DesHDAP3	  with	  proline	  
residues	  shown	  in	  red.	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Interestingly DesHDAP1 was more potent than BF2 against E. faecalis, similarly potent 
against E. coli ATCC 29212, S. marcesens, and B. subtilis, and less potent than BF2 against E. 
coli Top10 and S. aureus23. Although differences in absolute potency were expected when 
peptides were applied to different bacterial strains, it would be predicted that the relative 
efficacies of the different peptides should be fairly consistent. That is, stronger peptides should 
always be more effective than weaker peptides regardless of bacterial strain. This is not the trend 
that was observed, and the origins of the species-dependent changes in relative efficacies remain 
unexplained. Notably the observed pattern does not correlate with gram-positive versus gram-
negative bacteria as might be expected if the presence of a cell wall were responsible for these 
changes. 
Bacterial populations in solution are often measured by observing the turbidity from 
intact bacteria scattering light. Previous studies have also used this phenomenon to characterize 
the effects of cytolytic agents because lysed bacterial cells fail to scatter light in a similar matter 
so the application of a cytolytic agent results in a rapid decrease in optical density21. When the 
lytic activities of the designed peptides were analyzed in this manner, DesHDAP1 demonstrated 
a profile similar to that of BF2, characterized by an increase in absorbance despite the fact that 
cells in solution have already become nonviable as measured by ability to grow overnight on 
agar plates. However both DesHDAP2 and 3 demonstrated profiles with the drop in absorbance 
characteristic of lysing cells. In order to understand these observations and evaluate whether the 
common features of the novel HDAP design were sufficient to confer peptides with a similar 
antimicrobial mechanism, we sought to characterize the antibacterial mechanisms of the novel 
DesHDAPs.  
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Because presence of the proline hinge is so critical to the function of BF2, each novel 
HDAP was also designed to include a single proline residue. In order to evaluate whether the 
proline plays a similar role in the antimicrobial mechanism of the novel HDAPs, the 
translocation, permeabilization, and overall antimicrobial abilities of the designed peptides were 
compared to the abilities of proline-to-alanine mutants.  
3.1 Designed HDAPs do not share a mechanism of action 
BF2’s antimicrobial potency is dependent on its ability to cross bacterial and lipid vesicle 
membranes32,58.  The absorbance profiles of bacteria exposed to DesHDAP1 resemble those of 
BF2, suggesting that it too might use a translocation-based antimicrobial mechanism23.  In 
contrast, the absorbance profile of cells exposed to DesHDAP3 shows a dramatic drop in 
absorbance, signifying cell lysis. This effect suggests that, unlike DesHDAP1, DesHDAP3 may 
not share a mechanism with BF2.  The designed peptides’ translocation abilities into bacteria 
were assessed qualitatively using confocal laser microscopy.  In these experiments, E. coli were 
exposed to biotinylated DesHDAP1 and DesHDAP3 and visualized with a streptavdin-
AlexaFluor488 conjugate.  Like BF2, DesHDAP1 generally appeared to be internalized by 
bacteria that showed fluorescence (figure 3A).  In contrast, DesHDAP3 showed little entry into 
cells and was primarily localized to bacterial cell membranes (figure 3B).  






The designed HDAPs’ translocation abilities were also assessed more quantitatively 
using the vesicle based translocation assay previously used by Matsuzaki and co-workers to 
characterize the function of BF259.  In this assay, the native tryptophan residues in each peptide 
act as FRET donors when associated with the dansylated lipids in the 50:45:5 
POPC:POPG:DNS-POPE lipid vesicles, producing a fluorescent signal. As peptides cross the 
lipid bilayer, they are digested by trypsin trapped within the vesicle, leading to a loss of FRET 
signal. To control for loss of FRET signal due to incomplete inhibition of the trypsin outside 
vesicles or other factors unrelated to translocation ability, the FRET signal between the peptide 
and vesicles encapsulating both trypsin and trypsin inhibitor was also monitored.  A significant 
Figure	  3.	  	  Localization	  of	  DesHDAP1	  (A),	  DesHDAP3	  (B),	  DesHDAP1	  P11A	  (C-­‐D),	  
DesHDAP	  3	  P13A	  (E)	  into	  E.	  coli.	  107	  CFU/mL	  bacteria	  were	  incubated	  with	  biotinylated	  
peptides	  (16	  µg/mL).	  	  Peptides	  localization	  was	  assessed	  following	  treatment	  with	  a	  
streptavidin-­‐AlexaFluor488	  conjugate	  and	  visualized	  on	  a	  Leica	  TCS-­‐SP1	  confocal	  
microscope	  with	  excitation	  at	  488	  nm.	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decrease in FRET signal as compared to the control is therefore indicative of a peptide that 
readily crosses membranes. 
 
 The drop in fluorescence observed for DesHDAP1 (figure 4B) is significantly greater 
than the drop observed in control vesicles containing inhibited trypsin.  In our experience, the 
relative fluorescence drop observed for DesHDAP1 is even larger than that observed for BF2 in 
our vesicle samples (figure 4A).   Together with the observed translocation into E. coli cells, this 
suggests that DesHDAP1, like BF2, is a cell-penetrating AMP that spontaneously crosses lipid 
membranes.  
Figure	  4.	  Translocation	  of	  BF2	  (A),	  DesHDAP1	  (B),	  DesHDAP3	  (C),	  DesHDAP1	  P11A	  (D),	  and	  
DesHDAP3	  P13A	  (E)	  across	  lipid	  vesicle	  membranes.	  Peptides	  (3	  μM)	  were	  exposed	  to	  lipid	  
vesicles	  (250	  μM)	  containing	  trypsin.	  The	  FRET	  signal	  at	  525	  nm	  (black)	  is	  plotted	  as	  the	  
fluorescent	  signal	  throughout	  the	  experiment	  relative	  to	  the	  initial	  fluorescent	  signal	  (F/Fo).	  
In	  control	  traces	  (grey)	  peptides	  were	  exposed	  to	  vesicles	  containing	  both	  trypsin	  and	  trypsin	  
inhibitor.	  	  
	   31	  
 In order to quantify the translocation, we averaged the ratio of the control and 
experimental signals over three independent experiments.  Our quantitative translocation ratio for 
BF2 is somewhat lower than the apparent value in data shown by Kobayashi et al59. This 
difference was likely due to the different sources of lipid (egg lipids versus chemically 
synthesized POPC and POPG used in this study) and different sources of trypsin and trypsin 
inhibitor.  However, our quantitative translocation ratios for both BF2 and DesHDAP1 are 
indicative of membrane translocation. In contrast, DesHDAP3 showed a much smaller decrease 
in fluorescence when compared to controls (figure 4C), indicating that it did not exhibit 
appreciable translocation (Table 3).   
 
Peptide Translocation ratio 
DesHDAP1 1.13 ± 0.08 
DesHDAP1 P11A  1.11 ± 0.01 
DesHDAP3 0.97 ± 0.04  
DesHDAP3 P13A 0.982 ± 0.005 
Buforin II 1.07 ± 0.06 
 
After translocating across the cell membrane, cell-penetrating AMPs must be able to 
reach and interact with their intracellular target(s). In BF2, DNA binding is correlated with 
overall potency, indicating that DNA binding is indeed critical to the bactericidal mechanism34. 
The DNA binding strength of DesHDAPs 1 and 3 was assessed by measuring the peptide 
concentration required to displace thiazole orange from double stranded DNA (Table 4). In this 
assay, DesHDAP1 bound DNA somewhat more weakly than BF2, which may partially explain 
Table	  3.	  Translocation	  of	  DesHDAP1,	  DesHDAP3	  and	  their	  proline	  to	  alanine	  mutants	  into	  
lipid	  vesicles.	  The	  reported	  translocation	  ratios	  represent	  the	  ratio	  of	  the	  retention	  of	  
fluorescence	  after	  25	  min	  of	  the	  translocation	  control	  to	  that	  of	  the	  experimental	  conditions.	  
Uncertainty	  is	  reported	  as	  a	  standard	  deviation.	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why BF2 is more potent against some bacterial strains than DesHDAP123.  In contrast, 
DesHDAP3 bound to DNA with approximately the same affinity as BF2.  However, since 
DesHDAP3 is unable to cross membranes effectively, its enhanced DNA binding would be less 
relevant for its antimicrobial activity.  Moreover, the differences in DNA binding between these 
peptides are relatively small and therefore likely less important in determining functional 





If DesHDAP3 does not function through effective translocation across lipid membranes, 
its antimicrobial activity may arise from an ability to permeabilize membranes.  To test this 
possibility, we measured membrane permeabilization with a propidium iodide (PI) based assay.  
PI is a membrane-impermeable DNA intercalator, so fluorescence is indicative of membranes 
that have been disrupted. Although these peptides do have some affinity for DNA, appreciable 
competition between peptide and PI binding should not occur because of the high DNA binding 
constant of PI and the 750-fold higher concentration of PI compared to peptide in these 
experiments.  Both designed peptides were relatively unable to permeabilize E. coli membranes 
(Table 5), showing a lower fluorescence from PI entering the cell than observed for BF2.  The 
observations that DesHDAP3 is less effective at membrane translocation and no better at causing 
Peptide  C50 (µM) Relative C50 
BF2 8.0 ± 1 1 
DesHDAP1 10.2 ± 0.5 1.28 
DesHDAP3 8.7  ± 1 1.09 
Table	  4.	  DNA	  binding	  of	  the	  novel	  HDAPs	  measured	  by	  fluorescent	  intercalator	  displacement.	  
The	  concentration	  of	  peptide	  required	  to	  decrease	  the	  fluorescence	  of	  thiazole	  orange	  by	  50%	  
(C50)	  was	  calculated	  by	  monitoring	  the	  decrease	  in	  fluorescence.	  Relative	  binding	  is	  normalized	  
compared	  to	  BF2.	  Uncertainty	  is	  reported	  as	  a	  standard	  deviation.	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membrane permeabilization than DesHDAP1 are consistent with the relatively lower 








3.2 The proline hinge plays a different role in the function of DesHDAPs1 and 3  
 DNA binding and translocation studies indicate that DesHDAP1 likely uses a 
mechanism similar to the one employed by BF2, while DesHDAP3 is significantly less able to 
translocate across membranes. Both BF2’s translocation ability and ultimately its bactericidal 
activity are closely tied to the presence of a helix-breaking proline hinge in its structure32,58, as 
mutating this proline to alanine significantly decreases the antimicrobial potency and 
translocation ability of BF2 while increasing its membrane permeabilization58,59.  Both 
DesHDAP1 and DesHDAP3 were designed to have an analogous proline hinge, so proline to 
alanine mutants of DesHDAPs 1 and 3 were generated to assess the role that the proline hinge 
plays in determining the mechanism and biological activity of these novel HDAPs.   
 F5 / F0 
 Wildtype Proline mutant  
BF2 1.29 ± 0.1 - 
Magainin 1.52 ± 0.2 - 
DesHDAP1 1.12 ± 0.06 1.06 ± 0.05 
DesHDAP3 1.13 ± 0.08 1.57 ± 0.4 
Table	  5.	  The	  effect	  of	  proline-­‐to-­‐alanine	  mutations	  on	  the	  permeabilizing	  ability	  of	  
DesHDAP1	  and	  DesHDAP3.	  Propidium	  iodide,	  a	  membrane	  impermeable	  DNA	  intercalator,	  
can	  enter	  bacterial	  cells	  only	  after	  membrane	  disruption.	  Data	  is	  presented	  as	  the	  ratio	  of	  
propidium	  iodide	  fluorescence	  at	  617	  nm	  5	  min	  after	  addition	  of	  2	  μM	  peptide	  to	  the	  
fluorescence	  before	  peptide	  addition.	  Uncertainty	  is	  reported	  as	  standard	  deviation.	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CD spectra of the peptides in a solution of 50% trifluoroethanol confirm the structural 
changes that result from the proline to alanine mutations (figure 5).  As observed previously23, 
the wild type DesHDAP1 peptide has a CD spectrum very similar to that of BF2, implying that it 
likely shares a partially helical structure with BF2, whereas wild type DesHDAP3 has 
significantly greater helical character.  As expected, the proline mutation increases the α-helical 
structure of both peptides.  However, the effect is more dramatic for the DesHDAP1 peptide, 
which was originally less helical.  
 
 
Antibacterial potency of the DesHDAP1 and DesHDAP3 peptides and their proline 
mutants was measured using a radial diffusion assay (figure 6).  As seen in previous studies, 
DesHDAP1 showed antibacterial activity similar to that of BF2, while DesHDAP3 had 
somewhat lower activity23.  Like BF2 P11A, DesHDAP1 P11A showed reduced activity against 
all bacterial species tested (figure 6A).  In contrast, removing the proline hinge improved the 
Figure	  5.	  Circular	  dichroism	  spectra	  of	  all	  peptides	  were	  taken	  in	  50%	  trifluoroethanol:	  50%	  
phosphate	  buffer	  solutions.	  A.	  CD	  spectra	  of	  DesHDAPs1	  (black)	  and	  DesHDAP1	  P11A	  
(gray).	  B.	  CD	  spectra	  of	  DesHDAP3	  (black)	  and	  DesHDAP3	  P13A	  (gray)	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bactericidal activity of DesHDAP3, as DesHDAP3 P13A showed greater activity against all 
bacterial strains than the parent peptide (figure 6B).  In fact, the potency of DesHDAP3 P13A is 
comparable to that of DesHDAP1 and BF2. 
 
In order to explain these divergent trends in activity for DesHDAPs 1 and 3, we 
characterized how the proline mutations altered the membrane translocation and 
permeabilization of the two peptides. The vesicle-based translocation assay suggested a slight 
decrease in DesHDAP1 P11A’s translocation abilities compared with wildtype peptide (Table 3, 
figure 4D), although this decrease was within the experimental error of our method.  Similarly, 
some bacteria exposed to DesHDAP1 P11A displayed peptide internalization, while others 
within the same slide showed localization of the peptide to the membrane (figure 3C-D).  
Together, these data suggest that the proline mutation may have reduced, but certainly did not 
eliminate, the efficiency of DesHDAP1 translocation.  This reduction in translocation efficiency 
may explain the decrease in DesHDAP1 P11A bactericidal activity and suggests that the proline 
hinge plays a similarly important role in peptide translocation for both BF2 and DesHDAP1.  
Figure	  6.	  The	  antibacterial	  activity	  of	  the	  original	  DesHDAP1	  (A)	  and	  DesHDAP3	  (B)	  
peptides	  (solid	  bars)	  and	  their	  respective	  proline-­‐to-­‐alanine	  mutants	  (white	  bars)	  were	  
assessed	  with	  a	  radial	  diffusion	  assay.	  Error	  bars	  represent	  standard	  deviations.	  	  
	   36	  
Like the wild type DesHDAP3, DesHDAP3 P13A showed minimal translocation in both lipid 
vesicle and bacterial studies (table 3, figure 3E, figure 4E).  This suggests that the proline hinge 
greatly aids in translocation for some HDAPs, but that the proline hinge alone does not 
necessarily confer translocation abilities.  
To assess whether any of the peptides might be working through a lytic mechanism rather 
than a cell-penetrating mechanism, membrane permeabilization in the presence of peptide was 
tested using the PI assay (Table 5). As shown above, both of the wild type DesHDAPs caused 
minimal membrane permeabilization. However, while DesHDAP1 P11A caused even less 
permeabilization than the wildtype designed peptide, DesHDAP3 P13A caused membrane 
permeabilization at a level comparable to magainin, a known lytic peptide60.  Thus, it appears 
that the P13A mutation enhances the antibacterial activity of DesHDAP3 by converting the 
peptide into a much more effective membrane-permeabilizing agent. 
 
3.3 Discussion 
This work with novel HDAPs confirms that histones can serve as effective templates for 
antimicrobial peptide design. Their success also confirms that using features of known peptides 
to design novel AMPs is a viable strategy. However, despite the similar characteristics and 
design strategy, the three DesHDAPs discussed here do not share a mechanism of action, 
indicating that some additional property or properties are involved in the determination of 
antimicrobial mechanism. Interestingly the potency of these peptides does not correlate with 
their helical natures, suggesting that factors other than solely helical content must affect 
antibacterial activity.  
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Additionally, the proline hinge served to disrupt the alpha-helical nature of each peptide, 
but the effect of this disruption on antibacterial potency differed markedly. Notably DesHDAP1 
became a weaker antimicrobial agent upon substitution of the proline residue with alanine 
because the peptide lost its ability to effectively cross lipid bilayers. In contrast neither 
DesHDAP3 nor its proline mutant were able to effectively cross lipid bilayers. Instead the 
increase in antibacterial activity upon proline-to-alanine substitution is likely a function of the 




DesHDAP3 has the most amphipathic character when in a fully helical conformation 
(figure 7), so seems plausible that the P13A mutation enhances antimicrobial activity because it 
allows the peptide to adopt a more ideal conformation for membrane interactions. Thus instead 
of using overall peptide helicity as a predictor of peptide potency, this study indicates that 
amphipathic character may be a more important determinant. For peptides such as DesHDAP3 
that form highly amphipathic alpha helices, disruption of the helix by a proline residue is 
detrimental to the overall potency because of the subsequent reduction of amphipathicity. In 
Figure	  7:	  HDAP	  helical	  wheel	  depictions	  generated	  using	  the	  GROMACS	  suite.	  Hydrophobic	  
residues	  are	  shown	  in	  grey,	  and	  the	  proline	  hinge	  is	  outlined.	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contrast peptides that form imperfectly amphipathic helices may benefit from proline disruption 
because the added flexibility allows the peptide to deform into a more amphipathic 
conformation.  
It is also notable that the effect of the proline residue correlates so well with the 
predominant mechanism of action. It is plausible that the flexibility of a proline hinge is more 
important for peptides crossing all the way through a lipid bilayer than for peptides functioning 
through lytic mechanisms. Indeed, rigid helices might even be preferable if the predominant 
mode of antibacterial activity requires the formation of regular pores, as seen in the toroidal pore 
or barrel stave models of membrane lysis (figure 8) Indeed, this effect has been seen in several 




Ultimately this study suggests that histones may be a fertile source of AMP template 
material but that histone homology alone does not predict a particular mechanism of action. In 
Figure	  8:	  Amphipathic	  helices	  have	  segregated	  polar	  and	  nonpolar	  faces	  (A).	  Amphipathic	  
helices	  are	  ideal	  for	  pore	  formation	  because	  the	  nonpolar	  surface	  forms	  and	  exterior	  that	  
can	  interact	  with	  the	  nonpolar	  lipid	  tails	  of	  the	  membrane	  interior,	  while	  the	  polar	  face	  lines	  
the	  inner	  aqueous	  pore	  (B).	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order to further explore the determinants of HDAP potency and mechanism, it will be imperative 
to gather a larger set of characterized HDAPs.  
  
	   40	  
4. DEVELOPMENT OF HIGH THROUGHPUT SCREENING 
 
High throughput screening (HTS) techniques allow researchers to investigate the 
properties of many peptides at once and identify those that possess particular features. While it is 
important that HTS protocols are sensitive enough to distinguish peptides that possess desirable 
characteristics from those that lack them, these assays are intended for identification rather than 
exhaustive characterization and can therefore be less sensitive than other techniques. Peptides 
identified through HTS can be further characterized using the same techniques used to study 
other designed peptides. For our purposes, effective HTS protocols must be capable of 
identifying peptides with antibacterial activity and desirable mechanistic qualities. We are 
specifically interested in characterizing the antimicrobial mechanisms of AMPs, therefore it is 
important to know not only that a peptide is capable of killing bacteria but also whether it does 
so through membrane lysis or a translocation-based system. While antimicrobial activity screens 
must necessarily be done in vivo, both permeabilization and translocation can be addressed in a 
simplified vesicle system. Ideally, permeabilization and translocation could be assessed using the 
same vesicle population, thus further minimizing the volume of peptide required to gather this 
preliminary characterization.  
 
4.1  Antibacterial activity 
4.1.1 LIVE/DEAD® Bacterial Cell Viability Assay (Invitrogen) 
Invitrogen’s LIVE/DEAD® bacterial cell staining kit was used to assess the viability of 
bacterial cells after incubation with antimicrobial peptides. This procedure depends on 
monitoring the relative fluorescence from two DNA-intercalating dyes: SYTO9 and propidium 
iodide (PI). Both dyes are DNA intercalators, but differ in their binding affinity and ability to 
permeate bacterial cells. Propidium iodide is a well-characterized DNA-intercalator with a high 
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DNA affinity and fluorescence upon intercalation. However, propidium iodide is unable to cross 
intact cell membranes, a property which has led to its widespread utility in cell permeabilization 
assays64–66. In contrast SYTO9 is a fluorescent dye with a weaker DNA binding affinity, which is 
capable of crossing intact cell membranes67–69. Therefore when live bacteria with intact 
membranes are exposed to both dyes, only SYTO9 will be capable of accessing the DNA 
causing the cells to stain green. In contrast cells with disrupted membranes allow both PI and 
SYTO9 to enter the cell and compete for DNA binding70. Since PI has a higher DNA binding 
affinity it outcompetes SYTO9, staining these cells red. In order to create a standard curve for 
the percentage of living bacteria in a sample, bacteria are incubated in either phosphate buffer or 
70% ethanol for one hour in order to create populations of live and dead bacteria, respectively. 
These live and dead populations are combined in known ratios and stained with the dye 





For initial characterization of this assay for cell viability purposes, Kanamycin, a known 
and well-characterized antibiotic, was used at twice its minimum inhibitory concentration. The 
Invitrogen instructional manual suggests determining the percent viability using the ratio of 
fluorescence at 530 nm to fluorescence at 630 nm70. While this ratio produces an excellent 
standard curve for the combinations of live and ethanol-killed bacteria, the ratio suggested high 
cell viabilities for bacteria treated with antibacterial agents (table 6). Although the negative 
 
Em 530 Em 630 ratio % alive 
H20 8877.8 865.1 10.3 120.2 
Kan 5680.3 311.6 18.2 217.8 
BF2 7417.5 594.1 12.5 147.5 
Table	  6:	  Representative	  LIVE/DEAD	  ratios	  from	  9/30/12.	  Percent	  viability	  was	  calculated	  
from	  the	  standard	  curve	  of	  ethanol-­‐killed	  bacteria.	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control population treated only with water showed a fluorescence ratio comparable to the 100% 
live standard, bacteria treated with kanamycin consistently produced ratios suggesting greater 
than 100% viability (table 6). Further investigation revealed that these high ratios were a result of 
a dramatic decrease in propidium iodide fluorescence in these bacteria as compared to any of the 
other populations from the standard curve. In order to confirm that the laboratory stock of 
Kanamycin was indeed acting as an effective antibacterial agent, bacterial solution was removed 
immediately prior to staining, plated on LB agar, and allowed to grow overnight. These plates 
revealed that the kanamycin-treated cells were indeed non-viable by the time of the staining, 
while the control cells retained full replicative potential. 
In order to obtain a more complete understanding of the fluorescent spectra from these 
stained bacterial populations, the fluorimeter was used to obtain the spectrum of sample 
fluorescence from 490 to 700 nm (figure 9). Although the kanamycin-treated bacteria retained a 
peak at approximately 510 nm that was also present in control bacteria, the fluorescence 
decreased dramatically at the higher wavelengths. Notably, the propidium iodide fluorescence in 
the 620-650 nm range was lower for the kanamycin-treated cells than for any of the standard 
conditions, including those with completely live bacteria where propidium iodide is considered 
to be completely excluded from cells. 
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The observation that the PI fluorescence for kanamycin-treated cells is even lower than 
that observed from completely healthy cells with intact membranes suggested that there could be 
direct interactions between the antibiotic and the dye molecules. Kanamycin functions through 
ribosome inhibition and would therefore not be predicted to affect DNA intercalating behavior of 
either PI or SYTO964. On the other hand, ribosomes contain significant portions of RNA71 and 
ssDNA probes have been designed to detect the presence of kanamycin72, suggesting that the 
antibiotic is capable of at least some forms of nucleotide interactions. While literature searches 
revealed no evidence of documented kanamycin-PI interaction, the existence of interactions that 
prevent PI from binding to DNA or that quench its fluorescence could explain the observed 
changes in fluorescence.  
Figure	  9:	  Fluorescence	  spectrum	  of	  108	  CFU/mL	  E.	  coli	  incubated	  with	  propidium	  iodide	  
and	  SYTO9	  dyes.	  Standardization	  solutions	  were	  prepared	  by	  combining	  ethanol-­‐killed	  
bacteria	  with	  bacteria	  incubated	  in	  buffer	  in	  appropriate	  ratios.	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Confocal microscopy confirmed the spectroscopic observation that kanamycin-treated 
cells demonstrate robust SYTO9 staining at least comparable to that of live control cells (figure 
10). However, kanamycin-treated E. coli were unable to grow overnight on LB agar, confirming 
that they were non-viable by the time of imaging.  Because kanamycin functions through 
ribosome inhibition, it is possible that these cells could become non-viable significantly before 





In addition to the practical difficulties encountered during the attempt to implement this 
assay for antibacterial screening, some of the premises of the LIVE/DEAD® assay may argue 
against its appropriateness for use in antibacterial discovery. Firstly, the creation of the standard 
curve with live and killed bacteria assumes that a bacterial mixture can be adequately described 
with these binary states. In this model all cells that are alive are perfectly healthy and equivalent, 
while all dead cells are likewise completely permeable. This model has been used effectively for 
the characterization of mixed bacterial populations, such as biofilms, but is unlikely to accurately 
Figure	  10:	  Confocal	  images	  of	  live	  (a)	  and	  ethanol-­‐killed	  (b)	  E.	  coli	  demonstrate	  
appropriate	  staining	  by	  live/dead	  dyes.	  Bacteria	  treated	  with	  2	  mg/mL	  kanamycin	  
demonstrate	  robust	  Syto9	  staining	  (c)	  but	  are	  non-­‐viable.	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portray the condition of bacteria exposed to antibacterial agents. Instead, bacteria exposed to 
antibacterial agents are likely to be unhealthy or physiologically stressed prior to complete cell 
death, states which this assay is not equipped to detect. Furthermore, the assay actually assesses 
membrane integrity rather than cells’ ability to survive and reproduce. If the difficulties thus far 
observed are at least in part due to the fact that bacteria are being dyed after they have become 
non-viable but before the subsequent breakdown of membrane occurs, it follows that this assay 
might be more valid if the post-exposure window were lengthened. While the membranes of the 
non-viable bacteria observed here appear to remain largely intact up to 45 minutes after exposure 
to antimicrobial agents, it is possible that the same dying procedure applied after several hours 
might be able to identify bacteria which have begun to break down as a result of antimicrobial 
agent induced death. Although lengthening the timescale might allow this assay’s use for 
antimicrobial screening purposes, the LIVE/DEAD® assay is not optimally designed for 
screening novel agents. Instead, research efforts were redirected toward identifying another, 
more appropriate assay.  
 
4.1.2 Turbidity-Based Assay 
Many antimicrobial screens use relatively simple assays for antibacterial activity that 
involve monitoring the turbidity of bacteria after an overnight incubation with the putative 
antibacterial agent73,74. While microbroth dilution assays vary the concentration of the 
antibacterial agent and are used to assess the minimum inhibitory concentrations of compounds 
known to have antimicrobial activity, a simpler assay can use untested compounds at some 
threshold concentration to assess whether or not they have appreciable antimicrobial activity 
warranting further study.  
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The initial antibacterial challenge is performed on bacteria in a nutrient poor testing 
medium in order to minimize bacterial growth during the exposure window and to eliminate the 
possibility of interactions between peptides and growth media. A 1 x 103 CFU/mL solution of 
log-phase bacteria in liquid testing media was added to wells of a 96-well plate containing an 
appropriate concentration of antibacterial agent and incubated for 3 hours at 37oC. After this 
interval, a 2X nutrient broth was added and the plates were allowed to grow overnight. The 
following day wells were characterized using a binary growth/no-growth designation because all 
wells that demonstrated bacterial replication exhibited similar turbidity beyond the range 
quantifiable by a spectrophotometer. Quantitative characterization of turbidity would have been 
further inhibited by the heterogeneity of the bacterial suspensions; significant colonies of 
bacteria had settled to the bottom of the well because the overnight incubation did not include 
agitation. Because turbidity did conform well to a binary scoring system and there was good 
consistency between wells from the same treatment, this scoring system was deemed appropriate. 
As with the previous assay of antibacterial activity, kanamycin (0.2 mg/mL) was used as 
a positive antibacterial control and an equal volume of sterile water as a negative control. While 
both positive and negative control wells displayed appropriate growth behaviors, neither buforin 
II nor DesHDAP1 caused any inhibition of cell growth at concentrations up to 30 µM (figure 
11). Although a MIC has never been determined for DesHDAP1, literature values for BF2 MICs 
cite values of 2-4 µg/mL13,32,58, or 0.8-1.6 µM. Although the peptides tested here demonstrate 
antimicrobial activity in an agar diffusion assay, indicating that they have not degraded, they are 
unable to inhibit growth in liquid medium even at concentrations approximately 10 times the 
published MIC.  
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At present, we have no satisfactory explanation for this failure of BF2 to inhibit bacterial 
growth in solution. E. coli strain may play a role, as we used Top 10 while many of the studies 
cited previously use other strains. However, it seems unlikely that such large discrepancies in 
efficacy are due entirely to differences in laboratory strain susceptibility. At least one recent 
paper has reported a similar inability of BF2 to retard bacterial growth in solution. Lan et al 
observed that BF2 did not cause any growth inhibition of either Top 10 or NCTC9001 E. coli at 
peptide concentrations up to 26.30 µg/mL (10.8 µM), the highest concentration tested in their 
experiment75. However, they fail to provide any explanation for this anomaly, incorrectly citing 
differences in technique as the likely source of this disagreement. Despite the lack of satisfactory 
explanation, this seems to be evidence of a similar problem in the hands of other investigators. 
Performing this assay with other well-characterized AMPs would provide further evidence 
regarding whether the observed issues derive from the activity of BF2 itself or from the assay 
protocol used in our lab.  
 
 4.2 Membrane Permeabilization 
4.2.1 Calcein Leakage 
Calcein is a fluorescent dye often used for cell staining and for interrogation of vesicle 
volume and dynamics. Calcein is a particularly useful because it exhibits strong self-quenching 
Figure	  11:	  Overnight	  growth	  of	  E.	  
coli	  after	  treatment	  with	  water,	  2	  
mg/mL	  kanamycin,	  30	  μM	  BF2,	  or	  
20	  μM	  DesHDAP1.	  Grey	  cells	  
indicate	  significant	  bacterial	  growth	  
in	  a	  well	  after	  17	  hours.	  Boxes	  in	  
the	  same	  row	  represent	  replicates	  
of	  a	  condition.	  	  
	   48	  
behavior at concentrations above 4 mM76. While the mechanism of this self-quenching is not 
entirely understood, it appears to result from dimerization into a non-fluorescent form coupled 
with energy transfer from monomers to dimers77. Because of this property, calcein and similar 
molecules are often used for investigation of vesicle volumes, fusion, or leakage. 
Düzgüneş et al describes a dye leakage assay performed by encapsulating calcein at 35 
mM within phospholipid vesicles and monitoring for an increase in fluorescence upon membrane 
disruption and subsequent release of calcein into the extravesicular solution78. After usual vesicle 
preparation in a solution of concentrated calcein and extrusion, the vesicle solution was purified 
on a gel-filtration column in order to separate the vesicles from the extravesicular calcein in the 
solution. The color of calcein solutions made this process particularly easy because it was 
possible to identify vesicle fractions by their characteristic orange color while unencapsulated 
calcein had a lighter fluorescent green appearance.  
Positive and negative vesicle lysis controls were established by incubating the vesicles 
with 2 µL of Triton-X or ddH2O, respectively. Both 1% and 10% V/V Triton-X100 were used in 
our trials because some initial data suggested that magainin showed an intermediate 
permeabilization level compared to 10% Triton-X100 but was indistinguishable from 
permeabilization caused by 1% Triton-X100. Ultimately this appears not to be the case (Table 5) 
because both concentrations are well above the critical micelle concentration for Triton-X10078 
and subsequent trials were approximately as consistent between detergent concentrations as 
within trials of the same detergent concentration.  
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Ten minutes of treatment with 6 µM magainin caused an increase in fluorescence from 
the vesicle solution comparable to that caused by detergent above the critical micelle 
concentration. In contrast, vesicles exposed to 6 µM buforin II consistently exhibited less 
fluorescence than vesicles treated with only water  (figure 12). Both magainin and buforin, for 
which the most trials were conducted, produced at least one significant outlier. This makes it 
difficult to confidently interpret the single or even duplicate values collected for Des3P13A and 
Hipposin P26A and P26A/P48A.  
 









Jan 24 91.6 -38.2    
Jan 24 110.3 -33.2 6.9   
10% Triton-
X100 
Jan 17 43.9 -27.7    
Jan 29 105.9 -0.5 -30.1 23.4 -37.4 
Jan 29 111.3 -24.7 -18.9 25.2 9.8 
Table	  7:	  Percent	  permeabilization	  of	  calcein-­‐containing	  vesicles	  as	  determined	  by	  
comparing	  the	  difference	  in	  fluorescence	  between	  wells	  treated	  with	  peptide	  and	  
those	  treated	  with	  water	  control	  to	  the	  difference	  in	  fluorescence	  between	  wells	  
treated	  with	  Triton-­‐X100	  and	  those	  treated	  with	  water	  control.	  Wells	  from	  the	  same	  
experiment	  are	  depicted	  in	  the	  same	  row.	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The outlying datapoints are less fundamentally concerning than the presence of negative 
percent permeabilization values. Based solely on the principles of self-quenching, there should 
be no mechanism for a peptide to decrease the level of fluorescence. Instead the observed 
decrease must be due to previously unconsidered factors, such as direct interactions between the 
peptides and the calcein molecules. Because calcein is anionic and our AMPs are polycationic, it 
would not be surprising to observe charge-based interactions between the two. The fluorescence 
(and solubility) of calcein itself is strongly pH dependent79, so charge-based interactions with 
cationic peptides could significantly affect the dye’s fluorescent behavior as well.  
Figure	  12:	  Representative	  plot	  of	  calcein	  fluorescence	  after	  vesicle	  treatment	  with	  peptide.	  
PC/PG	  vesicles	  encapsulating	  35	  mM	  calcein	  were	  treated	  with	  6μM	  peptide	  or	  equivalent	  
volume	  of	  water.	  While	  magainin	  treatment	  caused	  an	  increase	  in	  calcein	  fluorescence,	  BF2	  
caused	  a	  decrease	  in	  fluorescence	  to	  a	  level	  below	  that	  of	  vesicles	  exposed	  only	  to	  water.	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Furthermore, there is some research suggesting that the presence of surfactants such as 
triton, sodium dodecyl sulfate (SDS), or cetyltrimethylammonium bromide (CTAB) can affect 
the fluorescence behavior of calcein80. Interestingly the surfactants found to affect calcein 
fluorescence encompass diverse charges, including surfactants that are positively and negatively 
charged (CTAB and SDS respectively), as well as nonionic (triton). Specifically, Triton-X100 at 
concentrations greater than the critical micelle concentration significantly affected the 
fluorescence spectrum of calcein in HEPES, although the direction of the effect (enhancement or 
suppression of fluorescence) were inconsistent depending on the calcein concentration. This 
suggests that quantitative permeabilization assays using calcein may also suffer from interactions 
between the dye and surfactants used to obtain the 100% permeabilization positive control as 
well as from interactions between peptides and dyes. 
Ultimately the potential for interactions other than self-quenching means that calcein-
based assays will not provide reliable evidence of membrane permeabilization for antimicrobial 
peptide screens. While a self-quenching dye with less potential for intermolecular interactions 
with AMPs might accomplish the task, we elected to pursue other permeabilization protocols 
based on those that have been used successfully by other groups for similar assessments of 
peptide permeabilization.  
 
4.2.2 Tb3+/DPA Fluorescence 
Previous high-throughput vesicle analyses of permeabilization and translocation have 
utilized the interaction between terbium III and dipicolinic acid (DPA) to assess vesicle lysis57. 
In this assay terbium (III) is encapsulated within lipid vesicles and extravesicular terbium is 
removed by size exclusion chromatography. DPA is then added to the vesicle solution, but is 
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unable to interact with the terbium because it cannot cross intact lipid bilayers. Upon addition of 
a membrane-permeabilizing peptide, vesicles will release Tb3+ into the surrounding solution 
where it will interact with the DPA and produce a robust fluorescent signal more than 1000 times 
greater than the signal from unchelated terbium ions81. This phenomenon is observed as a 
significant increase in fluorescence intensity when 50 mM DPA is introduced to a solution of 25 
mM Tb3+ in HEPES (Figure 13). 
 
The Tb3+/DPA assay has several difficulties compared to the calcein-based assessment of 
permeabilization. Although it does not directly affect ease of performing the assay, Tb3+ is a 
heavy metal whose use requires appropriate waste disposal and management of contaminated 
materials. Additionally in our hands the inclusion of Tb3+ has seemed to exacerbate common 
problems with vesicle preparation, particularly difficulty extruding the vesicles through the 
membrane. Finally Tb3+ is colorless in solution, making the progression of vesicles and terbium 
Figure	  13:	  Fluorescence	  of	  50	  
mM	  Terbium	  (III)	  in	  HEPES	  
before	  and	  after	  the	  addition	  of	  
25	  mM	  DPA.	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through the size exclusion column much more difficult to monitor compared to the similar 
process with colored calcein vesicles. Indeed we have not yet completed the successful 
preparation of vesicles in order to examine the utility of this assay for peptide assessment. 
However, its previous use in similar screens suggests that further manipulations could lead to the 
adaptation of this assay for effective permeabilization studies. 
 
4.3 Trypsin Digestion Translocation Assay 
Peptides that do not exert their antimicrobial activity through membrane permeabilization 
must be able to cross the lipid bilayer in order to interact with or inhibit intracellular 
components. A variety of monitoring techniques have been developed to assess peptide 
translocation. While confocal microscopy using labeled peptides can provide qualitative 
evidence for translocation, many researchers have turned to lipid vesicles for quantitative 
translocation metrics55–57,73. Vesicle-based assays simplify the experimental system and ensure 
that any observed translocation activity is definitively the result of peptide-lipid interaction. 
Previous work in the Elmore lab has used a FRET-based trypsin degradation assay to 
observe the entry of the novel HDAPs into vesicles82. In this assay vesicles are prepared with 5% 
dansylated phosphatidylethanolamine (DNS-PE), which can undergo fluorescence resonance 
energy transfer (FRET) with tryptophan residues in membrane- associated peptides to produce a 
fluorescent signal59. These vesicles are reconstituted in a solution containing the proteolytic 
enzyme trypsin. After vesicle preparation and quantification, both the solution interior and 
exterior to the lipid vesicle contains trypsin. In order to prevent degradation of peptide in the 
extravesicular solution, a trypsin-chymotrypsin inhibitor is added at 10x the concentration of the 
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trypsin itself. Because the vesicles have already been formed, the inhibitor protein is unable to 
enter the vesicles and the interior trypsin remains uninhibited (figure 14) 
 
Upon addition of peptide to the vesicle solution, the peptide associates with the lipid 
membrane and a FRET signal is measured. As translocating peptides cross the membrane they 
encounter the uninhibited trypsin, which cleaves the peptides after lysine or arginine residues. 
These degraded peptide fragments can no longer associate with the lipid bilayer, resulting in a 
loss of fluorescence signal. Therefore a decrease in fluorescence as the experiment progresses is 
indicative of a peptide that is effectively crossing lipid bilayers. 
Because trypsin inhibition is incomplete even with the presence of excess inhibitor, it has 
proven essential to compare experimental trypsin degradation to that from vesicles where 
Figure	  14:	  Schematic	  of	  translocation	  assay.	  Experimental	  LUV	  samples	  are	  doped	  with	  
fluorescent	  dansyl	  POPE	  (black	  bars)	  and	  contain	  encapsulated	  trypsin	  (scissors)	  (A).	  Trypsin	  
inhibitor	  (red	  circle)	  is	  used	  to	  inhibit	  trypsin	  outside	  the	  LUVs.	  The	  LUVs	  are	  exposed	  to	  
peptide	  (purple).	  Peptide	  association	  with	  LUV	  membranes	  yields	  a	  FRET	  signal	  (green)	  that	  
decreases	  as	  translocating	  peptides	  encounter	  uninhibited	  internal	  trypsin.	  Both	  trypsin	  and	  
trypsin	  inhibitor	  are	  encapsulated	  in	  control	  LUV	  samples	  to	  measure	  decreases	  in	  FRET	  signal	  
unrelated	  to	  translocation	  (B).	  82	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intravesicular trypsin has also been inhibited. These control vesicles are rehydrated in a solution 
containing both trypsin and trypsin-chymotrypsin inhibitor (figure 14B). When peptide is added 
to these vesicles it can cross the lipid bilayer and enter the vesicles, but the inhibited trypsin will 
be incapable of cleaving the peptides. The peptides will therefore remain associated with the 
lipid membrane and continue to produce a detectable FRET signal.  
Because the inhibitor can affect absolute fluorescence values, it is most illustrative to 
normalize both experimental and control fluorescence values against the initial value shortly 
after peptide addition. In this way degradation is seen as a percent decrease compared to the 
initial fluorescence rather than an absolute value. The difference between the decrease observed 
from experimental and control conditions illustrates whether or not peptides are effectively 
crossing the lipid bilayer.  
Initial results using the plate reader to execute this assay suggest that this platform is both 
effective and capable of detecting similar values as compared to the fluorimeter. Notably 
peptides such as BF2 and DesHDAP1, which have been shown to translocate effectively by both 
the fluorimeter version of this assay and confocal microscopy (figures 3 and 4), show a clear 
distinction between the control and experimental conditions (figure 15). Furthermore the 
quantitative values obtained by comparing the fluorescence in the last minute of a 25 minute 
observation to the initial fluorescence produces a ratio similar to that described using the 
fluorimeter (table 8). Additionally peptides such as Des3 P13A, which do not translocate, 
produce similar levels of fluorescence in the control and experimental conditions, although the 
noise in this trial prohibited quantitative analysis. While these results have not yet been 
replicated, this initial success suggests that the volume and instrumentation will not present 
obstacles to high throughput usage of this assay.  







Peptide Plate reader ratio 
Fluorimeter ratio 
(from table 3) 
BF2 1.17 ± 0.02 1.07 ± 0.06 
BF2 P11A 1.11 ± 0.006 - 
Des1 1.19 ± 0.05 1.13 ± 0.08 
Figure	  15:	  Translocation	  of	  peptides	  into	  lipid	  vesicles.	  Peptide	  translocation	  as	  
measured	  by	  fluorescence	  decrease	  upon	  entry	  into	  trypsin-­‐containing	  vesicles	  (solid	  
circles)	  as	  compared	  to	  vesicles	  containing	  inhibited	  trypsin	  (open	  circles).	  
Table	  8:	  Translocation	  ratios	  as	  measured	  on	  plate	  reader	  and	  fluorimeter.	  The	  reported	  
translocation	  ratios	  represent	  the	  ratio	  of	  the	  retention	  of	  fluorescence	  after	  25	  min	  of	  
the	  translocation	  control	  to	  that	  of	  the	  experimental	  conditions.	  Uncertainty	  is	  reported	  
as	  a	  standard	  deviation.	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The preparation and quantification of the vesicles for the translocation assay is both time 
consuming and difficult. Quantification of the phosphorus content in the control vesicles is 
particularly troublesome because the trypsin-chymotrypsin inhibitor is sold as a lyophilized 
powder in phosphate buffer. Thus the inhibitor solution adds additional phosphorus beyond that 
present from phospholipids in the vesicles. While it should be possible to use an appropriate 
volume of inhibitor solution to blank the quantification protocol for these vesicles, this has 
proven difficult. Specifically the samples containing the control vesicles have an absorbance 
very similar to the absorbance from the blank containing only inhibitor without any vesicles, 
making it difficult to accurately measure the lipid phosphorus content. Currently when such 
situations arise the concentration is assumed to be the same as the concentration of the 
experimental vesicles. However, because vesicles with inhibitor are typically much more 
difficult to extrude than those without, it seems likely that there are differences in final vesicle 
concentrations between the two samples. In the future in may be prudent to use dialysis to 
minimize or eliminate the phosphorus contribution of the inhibitor solution. However this buffer 
exchange could lead to a dilution of the inhibitor itself, making it more difficult to achieve the 
desired 1:10 trypsin: inhibitor ratio. 
A second concern about this assay involves the time delay between peptide addition and 
the onset of fluorescent monitoring. Because of the difficulties in vesicle preparation, there is 
insufficient solution for the usage of a multi-channel pipette. The necessity of adding vesicle to 
solution to each well, changing tips, and inserting the plate into the fluorimeter means that the 
“initial” reading recorded by the instrument does not in fact represent the maximum prior to any 
trypsin digestion. This would artificially deflate the apparent translocation, since the apparent 
initial value would be measured after some degradation. However, the fact that we do see 
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continued digestion over the course of our monitoring and that this value is quantitatively similar 
to fluorimetry suggest that the assay remains viable. Greater familiarity with the plate reader and 
strategic positioning of experimental wells could likely decrease, though not eliminate, this lag. 
  
	   59	  
5. FUTURE DIRECTIONS 
5.1 Antibacterial Activity: 
Previous characterizations of peptide efficacy in the Elmore lab have been performed 
using agar-based radial diffusion assays (RDAs) because they are easy to read, require little 
peptide, and give excellent data regarding the relative strengths of tested peptides. However it is 
difficult to extract quantitative information about inhibitory concentrations from RDAs because 
the diffusion of the peptide solution away from the well results in a logarithmic relationship 
between concentration and distance from the well. On a more fundamental level, the RDA does 
not test antimicrobial activity in a way that is reminiscent of the conditions that would be 
encountered in vivo. Bacteria suspended in the agarose medium are forced to grow in 
physiologically unnatural and primarily anaerobic conditions, which could affect their response 
to antimicrobial agents. In addition, the agarose gel itself might affect peptide properties or 
interact directly with the peptides. For these reasons, antimicrobial activity assessments 
performed in liquid medium likely provide a more valid measurement of true AMP potency.  
Turbidity based activity screening is straightforward, widely used in drug discovery, and 
not demanding in reagents, time, or technology. Based on these criteria such assays should be 
ideally suited to high-throughput activity screens in Wellesley laboratories. However, while both 
the positive and negative controls demonstrate appropriate growth conditions in this assay, none 
of the antimicrobial peptides tested inhibited bacterial growth at concentrations up to 30 µM. 
This is nearly 10x greater than the published MIC for BF213, though the laboratory stock of 
peptide is has been confirmed as an active antimicrobial agent in RDA measurements, indicating 
that it has not degraded.     
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Unfortunately, the simplicity of the turbidity screening assay makes it particularly 
difficult to identify potential sources of error. Attempts to more closely mimic the conditions 
used in successful literature applications may help through optimizing bacterial growth 
conditions or eliminating unforeseen inhibitory effects. While the low MIC’s generally 
acknowledged for BF2 have been widely replicated, the one paper reporting similar troubles 
observing inhibition from BF275 could represent another valuable source for identifying any 
factors contributing to our seemingly anomalous results.  
Alternately, there are some bacterial cell viability assays that measure cell death through 
other mechanisms. Metabolic assays present one such promising avenue. Much like the MTT 
assay commonly used to assess eukaryotic cell viability83, these assays measure bacterial health 
based either on the presence of key metabolic components or on the ability of living cells to 
metabolize one compound into a spectroscopically distinct metabolite. For example, the 
BacTiter-GloTM system from Promega measures metabolically active cells through quantification 
of ATP levels, while carboxyfluorescien and related compounds are cleaved by esterases to 
produce fluorescent products, and rhodamine 123 staining identifies cells capable of maintaining 
appropriate cell potential84. These physiological state probes may be capable of identifying 
bacterial responses to peptide treatment on a more relevant timescale than that required for 
membrane disruption, and additionally may more accurately reflect intermediate levels of cell 
function. This type of assay could also provide information about peptide mechanisms by 
suggesting specifically impaired cellular functions, and indicate useful directions for further 
explorations of peptide mechanisms.  
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5.2 Permeabilization; 
 The terbium (III)/DPA interaction has previously been used to assess permeabilization in 
similar high-throughput vesicle screens57. One major advantage of this method is the fact that the 
chemistry is orthogonal to the translocation assay implemented here and therefore can be 
performed simultaneously on the same vesicle population. In order to implement this assay in the 
laboratory, current issues with terbium encapsulation and vesicle extrusion will need to be 
addressed. Vesicle production is inherently a temperamental procedure, so the previous 
difficulties in producing these vesicles may not indicate a fatal flaw. Ultimately, terbium is 
approximately 1% of the size of trypsin, so from a steric point of view it should not present any 
greater trouble with respect to encapsulation within vesicles or passage through membrane pores. 
It is possible that the charge on the ion contributes to the observed difficulties, although the salts 
of the buffer should minimize any such effects. In their high-throughput screen using Tb3+/DPA 
interactions to report permeabilization, Marks et al used vesicles with a greater composition of 
PC relative to PG, which could also affect the ease of encapsulation57. It seems likely that 
successful implementation of this assay will simply require dedicated time and effort to 
determine conditions and adjustments for optimal vesicle production. 
 
5.3 Translocation 
Initial results adapting the vesicle based translocation assay to the high throughput plate 
format are promising, indicating a reasonable degree of internal consistency and ability to 
distinguish between translocating and non-translocating peptides. These data would be further 
supported by a systematic characterization of our DesHDAPs and their proline mutants using this 
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assay format. This complete series of experiments would allow a thorough comparison of the 
absolute values, consistency, and relative relationships between translocation abilities of peptides 
obtained using both the plate reader and fluorimeter assay systems. In the limited trials reported 
here, translocation values obtained from the plate reader do seem to be consistently higher than 
the equivalent values obtained from the fluorimeter, suggesting that direct comparison between 
instrumentation systems could be difficult. However, as long as relative values within a plate 
remain fairly consistent, this should not be overly problematic for the future of high-throughput 
screening because the most important comparisons will be those between peptides in the same 
library.  
A bigger problem may arise from the delay between addition of peptide to solution and 
the onset of measurement. Two factors contribute to this delay: lag time inherent in the plate 
reader system and delays introduced by the sequential filling of wells. The former is likely to be 
more easily addressed than the latter. The delay between inserting the tray into the plate reader 
and pressing “read” and the onset of the first actual reading may be reducible by manipulating 
instrument and software settings appropriately. However, the inherent delay (and offset between 
wells) introduced by sequential addition of vesicles to wells is a more significant issue that will 
only increase in importance as the scale of this testing continues to increase. Generally, high-
throughput formats can be used to interrogate time-sensitive kinetics assays if a multi-channel 
pipette is used to add solution to 8 or 12 wells simultaneously, thus dramatically reducing the 
time required to fill a plate. However, a significant volume of solution is required in order to be 
drawn up into a multi-channel pipette, effectively prohibiting the use of this instrument on 
volume-limited reagents. In this particular assay the vesicle solutions, particularly the control 
vesicles containing inhibited trypsin, are produced in a volume only just sufficient to fill the 
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wells. While vesicle production could be scaled up, both the DNS-PE lipid and the trypsin 
inhibitor are among the most expensive components of this assay and the multi-channel pipette 
troughs inevitably retain a non-trivial volume of wasted solution. Ultimately the ability to rapidly 
add solution to the wells of a plate may be one of the limiting factors in the scale of this assay. 
Extending the timecourse over which the change in fluorescence is monitored could minimize 
the importance of differences in start time. Monitoring for longer than 25 minutes was never 
considered feasible in fluorimeter-based experiments and therefore has not yet been explored on 
the plate reader. If the fluorescence were monitored and found to decrease consistently for longer 
periods such as one hour, differences of seconds or even minutes in initial peptide addition 
would presumably become virtually unimportant. In any case, when compared to the sequential 
nature of assays performed on the fluorimeter, the ability to perform even a dozen assays in 
parallel represents a significant and appreciable improvement in throughput.  
 
5.4 Applications 
Successful development of high-throughput screens for peptide activity and mechanism 
will be essential for the future of peptide screening and investigation in the both Elmore lab and 
more generally in the AMP field. Although these techniques can be used to enable screening of 
large peptide libraries, they can also be used to gather initial information about smaller sets of 
peptide variants in order to probe a particular question.  
One area that has piqued the interest of AMP researchers is the effect of the identity of 
the charged residues found in polycationic AMPs. While both lysine and arginine carry a 
positive charge at physiological pH, the guanidinium group of arginine is capable of forming 
multiple hydrogen bonds, affecting its interactions with lipid membranes. Although predictions 
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would suggest that arginines would be highly unfavorable in transmembrane helices, both 
partitioning studies and mutagenic studies using proteins in biological systems confirm that 
arginine can and does function as part of transmembrane helices85. It is hypothesized that 
extensive hydrogen bonding to inwardly deformed lipid heads and water molecules may 
contribute to this phenomenon. Arginines are also common in permeabilizing AMPs and CPPs86, 
supporting the fact that this residue can interact with lipid bilayers in meaningful ways.  
In fact, there is evidence that not only the charge, but also the chemical properties of 
cationic side chains can affect the activity and mechanism of AMPs. Substitution studies with the 
AMP tritrpticin indicated that the identity of the cationic residues in a peptide could affect the 
peptide’s mechanism of action87. By replacing arginines with lysines or unnatural amino acids 
with positively charged side chains, this study determined that residues capable of extensive 
hydrogen bonding interactions caused greater membrane disruption than equivalently charged 
residues unable to make those associations. Based on this information, it would be interesting to 
assess whether substituting arginine/lysine residues on BF2 or the designed peptides would affect 
their activity and/or mechanism of action. High-throughput screening would allow for rapid 
assessment of the many permutations and combinations of substitutions possible in these 
peptides. 
The introduction of effective high-throughput screens will have the greatest impact on the 
ways in which novel AMPs are discovered. Previous work in the Elmore lab approached the 
design of new peptides by searching for fragments of histone sequences that conformed to given 
characteristics. Although all three peptides developed in this manner did display some 
antimicrobial activity, DesHDAP2 was a weak antimicrobial agent and was subsequently ignored 
for the mechanistic studies described earlier in this thesis. Furthermore, complete 
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characterization of these three peptides and their mechanisms required three years of study by 
multiple undergraduate researchers. High throughput screening techniques open the door for 
screening larger libraries of randomly or rationally designed peptides. Peptides identified by 
these screens with good activity and desirable mechanistic characteristics could then be carefully 
characterized using fluorimeter-based screens or used as the basis for new libraries. This type of 
approach could be used to explore the potential AMP activity of other histone fragments or to 
design a semi-random library of peptides with characteristics such as proline hinges or differing 
amphipathic character 
Increased information from these studies may be able to expand the current 
understanding of what features contribute to effective antimicrobial peptides and determine 
particular mechanisms of action. This will ultimately enable more effective modification of 
existing peptides and design of novel peptides to address the need for novel antimicrobial agents 
for clinical applications.  
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